Enanta Pharmaceuticals, Inc. - Common Stock (NQ:ENTA)

10.65 +0.28 (+2.70%)

Delayed Quote Updated: 4:00 PM EST, Nov 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Enanta Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

What 7 Analyst Ratings Have To Say About Enanta Pharmaceuticals ↗

October 20, 2021

Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ra...

Via Benzinga

Enanta Plans To Start Human Trials For Its COVID-19 Candidate In 2022 ↗

October 19, 2021

Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has reported new preclinical data for EDP-235, its recently announced lead oral protease inhibitor for COVID-19. ...

Via Benzinga

Enanta Pharmaceuticals Presents New Data for EDP-235, its Lead Oral Protease Inhibitor Designed for the Treatment of COVID-19, at the ISIRV–WHO Virtual Conference 2021

October 19, 2021

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Where Enanta Pharmaceuticals Stands With Analysts ↗

October 07, 2021

Analysts have provided the following ratings for Enanta Pharmaceuticals (NASDAQ:

Via Benzinga

New Preclinical Data for EDP-235, Enanta’s Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19, to be Presented at ISRIV-WHO Virtual 2021 Conference: COVID-19, Influenza and RSV: Surveillance-Informed Prevention and Treatment

October 06, 2021

From Enanta Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO ↗

August 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (...

Via Benzinga

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology ↗

October 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:...

Via Benzinga

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs ↗

October 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021 ↗

October 07, 2021

Upgrades For State Street Corporation (NYSE:

Via Benzinga

Enanta Pharmaceuticals to Present at the H.C. Wainwright 2nd Annual Hepatitis B Virus Virtual Conference

October 05, 2021

From Enanta Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results ↗

October 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc...

Via Benzinga

Enanta To Discontinue Internal Development Of NASH Candidates ↗

October 04, 2021

After looking at interim phase 2b data, Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has decided to stop the monotherapy trial of EDP-305 for non-alcoholic...

Via Benzinga

Enanta Pharmaceuticals Provides Update on NASH FXR Agonist Programs

October 04, 2021

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Announces Data Presentations at AASLD’s The Liver Meeting® 2021

October 01, 2021

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Participate in Investor Conferences in September

September 07, 2021

From Enanta Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study ↗

September 16, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC)...

Via Benzinga

Enanta Pharmaceuticals Elects Yujiro S. Hata to its Board of Directors

August 23, 2021

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021 ↗

September 09, 2021

Upgrades According to Benchmark, the prior rating for TopBuild Corp (NYSE:

Via Benzinga

Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-721, Its Oral Hepatitis B Virus RNA Destabilizer

August 16, 2021

From Enanta Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself ↗

September 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Abbott Laboratories (NYSE:...

Via Benzinga

Enanta Pharmaceuticals, inc (ENTA) Q3 2021 Earnings Call Transcript ↗

August 06, 2021

ENTA earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Enanta Pharmaceuticals: Q3 Earnings Insights ↗

August 05, 2021

Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 67.61% year over...

Via Benzinga

The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab ↗

September 02, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) AbbVie Inc. (NASDAQ: ABBV...

Via Benzinga

Enanta Pharmaceuticals Reports Financial Results for Its Fiscal Third Quarter Ended June 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET

August 05, 2021

From Enanta Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering ↗

September 01, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31) AC Immune SA (NASDAQ: ACIU...

Via Benzinga

Enanta Pharmaceuticals Announces Nomination of Clinical Candidate EDP-235, its Lead Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19

August 05, 2021

From Enanta Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical ↗

August 31, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)...

Via Benzinga

Enanta Pharmaceuticals to Host Conference Call on August 5 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2021

July 29, 2021

From Enanta Pharmaceuticals, Inc.

Via Business Wire

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs ↗

August 01, 2021

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....

Via Benzinga

Enanta Pharmaceuticals Announces the Planned Retirement of Chief Medical Officer Nathalie Adda, M.D.

July 14, 2021

From Enanta Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.